Semi-Annual Statement Of Cash Flows

Carna Biosciences, Inc. - Filing #7345290

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Semi-annual statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-1,181,186,000 JPY
-1,130,846,000 JPY
-1,401,599,000 JPY
-1,323,399,000 JPY
Depreciation
35,612,000 JPY
33,808,000 JPY
Impairment losses
4,562,000 JPY
44,578,000 JPY
Interest expenses
3,451,000 JPY
5,310,000 JPY
Foreign exchange losses (gains)
-5,467,000 JPY
-19,670,000 JPY
Decrease (increase) in trade receivables
-599,720,000 JPY
1,069,478,000 JPY
Decrease (increase) in inventories
-21,609,000 JPY
-8,044,000 JPY
Increase (decrease) in trade payables
-762,000 JPY
-331,000 JPY
Other, net
29,790,000 JPY
-7,260,000 JPY
Subtotal
-1,640,892,000 JPY
-687,837,000 JPY
Interest paid
-3,365,000 JPY
-5,128,000 JPY
Net cash provided by (used in) operating activities
-1,677,464,000 JPY
-708,390,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-11,530,000 JPY
-125,831,000 JPY
Other, net
154,000 JPY
305,000 JPY
Net cash provided by (used in) investing activities
-11,376,000 JPY
-125,696,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
-119,988,000 JPY
-211,497,000 JPY
Redemption of bonds
-32,032,000 JPY
-28,028,000 JPY
Net cash provided by (used in) financing activities
1,182,027,000 JPY
367,006,000 JPY
Other, net
-9,290,000 JPY
JPY
Effect of exchange rate change on cash and cash equivalents
16,865,000 JPY
28,293,000 JPY
Net increase (decrease) in cash and cash equivalents
-489,947,000 JPY
-438,786,000 JPY
Cash and cash equivalents
2,889,101,000 JPY
3,379,048,000 JPY
3,817,834,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.